Market

Jasper’s drug pipeline will address unmet needs in breast/lung/ovarian/pancreatic cancer drugs market and multidrug-resistant cancer drugs market. Both the markets are part of the broader cancer drugs market with £100+ billion size and 8% compounded annual growth rate (CAGR).

Breast cancer drugs is a £15 billion market expected to grow at 11% CAGR from 2017-23. The market is divided into chemotherapeutic drugs, hormone therapy drugs and targeted therapy drugs. Current market leaders are AstraZeneca, Celgene, Roche and others.

Lung cancer drugs is a £16 billion market expected to grow at 13% CAGR from 2017-23. The market is divided into chemotherapy drugs, immunotherapy and targeted therapy. Current market leaders are F. Hoffmann-La Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Sanofi and others.

Ovarian cancer drugs is a 1.5 billion market expected to grow at 24% CAGR from 2017-23. Rising incidence of ovarian cancer, owing to growing geriatric population and unhealthy lifestyles, is one of the key trends escalating market growth. Generics and biologics including PARP inhibitors and VEGF inhibitors constitute 90% of all ovarian cancer drugs. Current market leaders include AstraZeneca, Roche, Tesaro, and Clovis Oncology.